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Objective To follow the evolution of capsular types and resistance of Streptococcus pneumoniae, isolated
from deep sites.
Methods More than100 Belgian laboratories permanently collect S. pneumoniae strains isolated from
puncture specimens (blood, cerebrospinal £uid, middle ear £uid, etc.) and forward them to the reference
center in Leuven, in order to determine the capsular serogroups and types (SGTs) and their resistance.
Results From1994 to1998, the 5486 S. pneumoniae strains examined belonged to 39 of the 46 currently
identi¢ed SGTs.The10most frequent SGTs accounted for 78.9% of the isolates, and 97% of all isolates
belonged to SGTs included in the 23-valent vaccine. Overall mortality of patients with pneumococcal
bacteremia or meningitis was 9.7%, and 23.8% in patients over 80  years. From1994 to1998, resistance to
penicillin (P) increased from 7.6% to14.2%, to tetracycline (T) from14.9% to 28.0%, and to erythromycin
(E) from 22.9% to 31%.Triple resistance (PTE) increased from 0.9% in1994 to 6.6% in1998. Five SGTs (6,
9,14,19 and 23) accounted for 50% of the isolates, but for>90% of the penicillin-resistant or
erythromycin-resistant isolates.
Conclusions Resistance of S. pneumoniae to penicillin, erythromycin and tetracycline is steadily increasing
and is concentrated in ¢ve serotypes included in the 23-valent pneumococcal vaccine. Increasing resistance
and highmortality of invasive infections are an incentive to vaccinate vulnerable groups.
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I N T R O D U C T I O N
Streptococcus pneumoniae is one of the most common causes of
upper and lower respiratory tract infections in children and
adults. S. pneumoniae is also among the most frequent causes of
bacterial meningitis and bacteremia. The case fatality rate in
bacteremic pneumococcal diseases increases with advanced
age [1].
Penicillin has long been the drug of choice for treating
infections caused by S. pneumoniae. However, since the 1960s
there has been a worldwide increase in reports of resistance to
penicillin and other antibiotics, including erythromycin, tet-
racycline and chloramphenicol [2].
S. pneumoniae strainswith diminished penicillin susceptibil-
ity (penicillin-resistant pneumococci or PRSP) characterized
by reduced a¤nityofpenicillin-bindingproteins forb-lactams
result from genetic recombination with other closely related
species. The prevalence of PRSP is partly explained by clonal
spread,andpartlybyhorizontalgenetransferwithinstrainsofS.
pneumoniae or between S. pneumoniae and viridans streptococci
[3,4].
In Belgium, rates of penicillin resistance increased from
0.9% in1985 to14.2% in1998. Both highly penicillin-resistant
(MIC  >  1  mg/L) strains and multidrug-resistant strains,
de¢ned as resistant to penicillin, erythromycin and tetracy-
cline, increased.
S. pneumoniae strains can be divided into 90 serotypes
based on di¡erences in antigen composition of the capsular
polysaccharides. For a few years, a vaccine containing 23 dif-
ferent pneumococcal capsular polysaccharides has been avail-
able and has been recommended for use in people over the age
of 60 and in high-risk individuals aged more than 2  years.The
23 types in the vaccine are responsible for more than 95% of
all pneumococcal invasive diseases in Belgium.
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In this paper we present the distribution of capsular types
of S. pneumoniae and their antimicrobial susceptibility in Bel-
gium during the period 1994^98. In a previous paper, data for
the period 1980^93 were reported [5]. We provide here also
some epidemiologic data on pneumococcal infections.
M A T E R I A L S A N D M E T H O D S
A national surveillance of invasive pneumococcal infections
was undertaken at the University Hospital Leuven from
October 1980 onwards. All isolates were typed, and antibiotic
resistance was determined.These pneumococci were collected
by more than 100 Belgian laboratories spread over the entire
country. They included six university hospitals, a large num-
ber of community hospitals and a small number of private
laboratories. Isolates were mailed to the reference laboratory as
cultures on blood agar together with a case report form con-
taining information on the age and sex of the patient, isolation
date and site of the original sample, and information on the
patient outcome (cure or mortality).
From 1994 to 1998, 5486 strains were isolated from either
blood or pleural £uid (74.6%), cerebrospinal £uid (CSF)
(5.1%), middle ear aspirates (18.6%) or various other puncture
sites (1.7%). Because the origin of the last group of strains was
heterogeneous (e.g. joint aspirates, peritoneal £uid, deep
abscesses), these strainswere not analyzed in terms of specimen
category; rather, these strains have been included only in the
general analysis of serotypes and resistance. Blood and pleural
£uid isolates from the same patient were only counted once
and were classi¢ed as bacteremic strains. Blood and CSF iso-
lates from the same patient were only classi¢ed as CSF strains.
In this surveillance study, no di¡erentiationwas made between
strains isolated from patients with community-acquired
infections and those isolated from patients with nosocomial
infections.
The identity of all isolates was ¢rst con¢rmed by examin-
ing the appearance of their colonies on blood agar and their
susceptibility to optochin. Subsequently, the strains were
typed by phase-contrast microscopy using Neufeld's reaction
with 46 type or group sera obtained from the Statens Serum-
institut (Copenhagen). According to the Danish typing sys-
tem, types yielding serologic cross-reactions have been
classi¢ed into 20 groups, each containing two to four sero-
types. The 46 test sera comprise the 20 group sera together
with 26 sera of a single serotype [6].
Susceptibility to penicillin G, tetracycline, erythromycin
and (from 1995) o£oxacin was tested by the standardized disk
di¡usion test on Mueller^Hinton agar containing 5% horse
blood agar according to the National Committee for Clinical
Laboratory Standards (NCCLS) recommendations [7]. An
inoculum density equivalent to 0.5 MacFarland standard was
prepared in trypticase soy broth. Plates were inoculated with a
sterile cotton-tipped swab and incubated overnight at 35  C in
a 5% CO2 incubator. Oxacillin (1  mg) disks were used to
screen for strains with diminished susceptibility to penicillin.
For all PRSP, the MICs of penicillin and cefotaxime were
determined on Mueller^Hinton blood agar plates with the
Etest (AB Biodisk, Solna, Sweden). The NCCLS interpreta-
tive criteria were used for the three categories of susceptibility
to penicillin G (R  0.06  mg/L for fully susceptible strains,
0.12^1.0  mg/L for intermediately resistant strains, and >1  
mg/L for highly resistant strains) and for cefotaxime (suscepti-
bleR0.5  mg/L, intermediately resistant>0.5 and<2  mg/L,
resistantr2  mg/L).
R E S U L T S
During the period 1994^98, 5486 isolates of S. pneumoniae
were received by the reference center. They belonged to 39 of
the 46 currently identi¢ed serogroups and serotypes (SGTs)
(Table  1). The 10 most frequent SGTs accounted for 78.9% of
the isolates. A comparison between the periods 1980^93 and
1994^98 showed a slight change in the SGTdistribution. The
seven most common SGTs were the same in both periods, but
the frequency of serotype 3 decreased from 8.1% in the ¢rst
period to 6.1% in the later period.
The order of frequency of other types such as 5 and 18 has
changed with time. The distribution of most serotypes was
found to be fairly similar among isolates originating from
patients with bacteremia, meningitis and otitis media. How-
ever, serogroup 1 was isolated with greater frequency from
blood than from other sources. In specimens from patients
with otitis media, SGTs 19, 6 and 23 represented 26.9%, 13.1%
and 13.4% of these isolates, respectively, while these three
SGTs accounted for only 8.1%, 8.5% and 6.8% of the isolates
frompatients with bacteremia.
The 23 vaccine types accounted for 97.5% of all isolates.
This calculation is based on the assumption that the types cho-
sen to represent groups in the 23-valent vaccine induce cross-
protection to the other types within their respective groups.
The only non-vaccine type representing >1% of all isolates
was SGT 24. In our study, SGT 24 was seventeenth in order of
frequency. SGTs 2, 17 and 42 are included in the 23-valent
pneumococcal vaccine but were rare in Belgium (0.09% of
isolates).
Every year there was a marked seasonal variation in the
number of isolates, with a major peak in December to March
(mean: 125.1 cases/month) and a trough in July to August
(mean: 38.2 cases/month). No seasonal trends were found for
individual SGTs.
Of a total of 5317 patients whose sex was reported, 3037 iso-
lates were from males and 2280 were from females (ratio 1.3).
The male predominance was observed for all types of speci-
men. Analysis of the age distribution of patients with severe
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pneumococcal infections showed striking di¡erences, which
are illustrated inTable  2.
Of a total of 3934 patients with blood and pleural isolates,
538 (13.7%) were children<5 years old, whereas they repre-
sented only 3.5% of the Belgian population in 1995. More
than 55% of pneumococcal bacteremias occurred in patients
>60 years old. CSF isolates came predominantly from
patients <5 and >40 years old. Middle ear isolates were
almost entirely (>  90%) recovered from children <10 years
old.
For the period 1996^98, we obtained information on out-
come for 1549 of the 2913 patients with pneumococcal bacter-
Table  1 Distribution by type or group of 5486 pneumococci isolated in Belgium (1994±98)
Distribution (%) of capsular types per indicated specimen
Pneumococcal type group Total no. of isolates
Blood and pleural ¯uid
(n  4090)
CSF
(n  277)
Middle ear aspirate
(n  1018)
Other specimens
(n  101)
14 705 (12.8) 12.4 13 15.1 6.9
19 634 (11.6) 8.1 8.3 26.9 6.9
6 515 (9.4) 8.5 7.9 13.1 11.9
1 481 (8.8) 10.5 4.7 3.3 3.9
9 450 (8.2) 8.9 10.1 5.1 3.9
23 445 (8.1) 6.8 7.6 13.4 9.9
3 334 (6.1) 5.7 5 7.3 12.9
5 290 (5.3) 6.4 2.9 2 1
4 253 (4.6) 5.6 5 0.5 3
7 220 (4.0) 4.8 2.9 1.4 1
8 183 (3.3) 4.2 3.6 0.4 2
18 151 (2.8) 2.9 6.5 1.3 3
22 100 (1.8) 2.1 2.5 0.5 2
12 99 (1.8) 2.1 2.5 0.1 4
15 99 (1.8) 1.6 2.9 2.3 4
11 92 (1.7) 1.5 2.2 1.7 8
24 87 (1.6) 1.8 2.2 0.6 2
33 70 (1.3) 1.3 1.2 1 3
10 67 (1.2) 1 3.6 1.4 0
38 37 (0.7) 0.8 0.3 0.3 2
20 26 (0.5) 0.5 0.3 0.3 0
16 21 (0.4) 0.4 0 0.2 1
35 21 (0.4) 0.4 1.1 0.2 0
Subtotal 5380
Others 106 (1.8) 1.6 3.7 1.5 8
Others: 2, 13, 17, 21, 27, 28, 29, 30, 31, 32, 34, 37, 39, 42, 45, 48.
Table  2 Percentage of patients in different age groups with isolates from blood±pleural ¯uid, cerebrospinal ¯uid and middle ear aspirates in
Belgium, 1980±93 and 1994±98
1980±93 1994±98
B
(4072)
CSF
(455)
ME
(754)
B
(3934)
CSF
(257)
ME
(911)
0±4 14.8 30.5 73.1 13.7 30 82.3
5±9 2.6 4.0 12.7 2.3 5.1 9.3
10±19 2.5 6.4 4.0 1.9 3.5 2.1
20±59 24.9 33.8 7 26.2 33.4 4.1
r  60 55.2 25.3 3.2 55.9 28 2.2
B, blood-pleural ¯uid; CSF, cerebrospinal ¯uid; ME, middle ear aspirate.
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emia and meningitis. Death occurred in 195 of 1549 (12.6%)
of the patients. However, the mortality increased with age
from 10 of the 435 children <10  years (2.3%) to 60 of 252
adults>60  years (23.6%).
Table  3 illustrates the mortality rate in patients for the
eight most frequent SGTs. The higher mortality in patients
with infections caused by SGTs 3, 6, 9, 19 and 23 can be
explained by the high prevalence of these SGTs in patients
>60  years; indeed, at least 54% of infections by these SGTs
occurred in patients of this group, in contrast to SGTs 1 and 5,
for which less than 37% and 33% of patients, respectively,
belonged to this age group.
Table  4 shows the evolution of antibiotic resistance of pneu-
mococci between 1988 and 1998 and the percentages of strains
resistant to penicillin G, cefotaxime, tetracycline, erythromy-
cin and o£oxacin. Strains with reduced susceptibility to peni-
cillin (MIC  >  0.06  mg/L) were detected for the ¢rst time in
Belgium in 1985. Before 1994, resistance to penicillin
remained<5%, but it increased to 7.6% in 1994 and further
to 14.2% in 1998. The prevalence of high-level resistance to
penicillin (MIC  >  1  mg/L) was less than 2% before 1993,
nearly absent during 1994^96, and 3% in 1998. Isolates with
reduced susceptibility to cefotaxime (MIC  >  0.5  mg/L) were
detected for the ¢rst time in 1995; thereafter, the prevalence of
these isolates increased to 5.8% in1998.
The prevalence of tetracycline-resistant pneumococci
£uctuated between 10.4% and 18% until 1996, but increased
to 23.2% in 1997 and 28% in 1998. Resistance to erythro-
Table  3  Distribution of capsular types over age and mortality (1996±98)
Number of patients with information on outcome
(number of deaths)
Capsular type (n) <  10 years 10±59 years r 60 years Total number of deaths (%) Unknown outcome
1 298 24 (0) 90 (1) 68 (3) 4 (2.2) 116
3 154 3 (0) 22 (9) 83 (17) 26 (24.1) 46
5 222 23 (0) 76 (1) 50 (14) 15 (10.1) 73
6 231 32 (3) 23 (17) 82 (13) 33 (24.1) 94
9 251 17 (0) 42 (12) 118 (16) 28 (15.8) 74
14 327 55 (2) 33 (9) 111 (10) 21 (10.2) 121
19 230 33 (3) 27 (15) 91 (7) 25 (16.6) 79
23 196 22 (0) 26 (8) 82 (13) 21 (16.2) 66
Table  4 Antimicrobial resistance of 8649 pneumococci isolated in Belgium, 1988±98
Percentage of strains resistant to indicated antibiotic
Penicillin G Cefotaximea
Year No. of isolates IR R IR    R IR R IR    R Tetracycline Erythromycin O¯oxacin
1988 382 2.8 0 2.8 0 0 0 10.4 11.5 NT
1989 520 2.6 0.2 2.8 0 0 0 16.7 12.3 NT
1990 540 3.0 1.1 4.1 0 0 0 17.0 17.0 NT
1991 536 1.5 1.7 3.2 0 0 0 14.4 15.7 NT
1992 551 2.7 1.3 4.0 0 0 0 15.4 19.2 NT
1993 641 2.3 0 2.3 0 0 0 12.6 21.5 NT
1994 751 7.5 0.1 7.6 0 0 0 14.9 22.9 NT
1995 992 7.0 0 7.0 0.1 0 0.1 15.8 24.1 0.4
1996 1289 8.6 0.9 9.5 2.1 0.1 2.2 18.4 25.9 0
1997 1241 9.3 0.6 9.9 1.6 0.1 1.7 23.2 28.6 0.2
1998 1205 11.2 3 11.5 5.6 0.2 5.8 28 31 0.1
IR, intermediate resistance; R, resistance. aCefotaxime only tested on pen-IR and pen-R isolates.
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mycin increased every year from 1986, the ¢rst year of
erythromycin screening, and reached 31% in 1998. Resistance
to o£oxacin remained very low (<  0.5%) during the eval-
uation period. Isolates from middle ear aspirates are signi¢-
cantly more resistant than isolates from blood cultures.
This observation is true for each year and for penicillin, tetra-
cycline and erythromycin. In 1998, 28.2% of middle ear
aspirates were resistant to penicillin and only 9.9% of blood
culture isolates. For tetracycline, the resistance percentages
were 40.1% versus 25.1%, and for erythromycin 54.3% versus
25.3%.
The MIC distribution for penicillin versus cefotaxime is
shown in Table  5. For 516 of the 541 pneumococci with
reduced susceptibility to penicillin, isolated since 1994, for
which MICs for penicillin and cefotaxime are available,
88.6% were moderately resistant and 11.4% highly resistant to
penicillin, and 20.2%were moderately resistant to cefotaxime
and only 0.8% highly resistant. For only ¢ve of the 532 pneu-
mococci were MICs for penicillin higher than 2  mg/L. For 14
(2.7%) strains, theMICs of cefotaximewere higher than those
of penicillin; for 335 (64.9%) strains, they were lower than
those of penicillin.
Table  6 illustrates the evolution of the antibiotic resistance
patterns found since 1994, in comparison with those found in
the previous period. The total percentage of pneumococci
resistant to one or more drugs has increased over the years.The
important and continuous increase in multidrug-resistant
(PTE) pneumococci is of particular concern.The average inci-
dence of these isolates increased from 0.3% for the period
1986^93 to 4.2% in 1997 and 6.6% in 1998. These strains
belong predominantly to SGTs 14 (35%), 23 (20%), 6 (19%)
and 9 (8%). Combined resistance to erythromycin^tetracy-
cline was present in 7.8% of the pneumococci during the per-
iod1986^93, but increased to16% in1998.
Table  5 Distribution of 516 pneumococcal strains with reduced susceptibility to penicillin according to the MICs of penicillin and cefotaxime
from 1994 to 1998
No. of strains for which the MIC of penicillin (mg/L) is
MIC cefotaxime (mg/L) 0.125 0.25 0.5 1 2 4 8
<  0.064 14 3 ± ± ± ± ±
0.125 14 37 15 ± ± ± ±
0.25 0 28 78 16 2 ± ±
0.5 3 5 67 115 9 2 ±
1 2 2 2 56 41 1 ±
2 ± ± ± ± 2 ± 2
Table  6 Comparison of antibiotic resistance pattern of pneumococci isolated in the period 1986±93 with those found since 1994
No. (%) of strains resistant during
Pattern
1986±93
(n    3366)
1994
(n    751)
1995
(n    992)
1996
(n    1297)
1997
(n    1225)
1998
(n    1205)
Susceptible to:
P, E and T 2631 (78.2%) 522 (69.5%) 691 (69.7%) 852 (65.7%) 780 (63.7%) 700 (58.1%)
Resistant to:
P alone 46 (1.4) 34 (4.5) 40 (4) 61 (4.7) 43 (3.5) 65 (5.4)
E alone 171 (5.1) 75 (10) 95 (9.6) 128 (9.9) 102 (8.3) 83 (6.9)
T alone 205 (6.1) 14 (1.9) 17 (1.7) 35 (2.7) 38 (3.1) 57 (4.7)
PT 37 (1.1) 9 (1.2) 5 (0.5) 15 (1.2) 11 (0.9) 9 (0.8)
PE 3 (0.1) 7 (0.9) 9 (0.9) 19 (1.5) 15 (1.2) 19 (1.6)
TE 262 (7.8) 83 (11.1) 119 (12) 160 (12.3) 184 (15) 193 (16)
PTE 11 (0.3) 7 (0.9) 16 (1.6) 27 (2.1) 52 (4.2) 79 (6.6)
P, penicillin; E, erythromycin; T, tetracycline.
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Table  7 illustrates the relationship between the di¡erent
SGTs and the occurrence of resistance to penicillin, tetracy-
cline and erythromycin in 1659 resistant pneumococci, iso-
lated from 1994 to 1998. Resistant pneumococci belonged to
29 di¡erent SGTs.The 541penicillin-resistant strains belonged
to17 di¡erent SGTs, but 97% of those were con¢ned to the six
SGTs classically associated with penicillin resistance: SGTs 6
(8.7%), 9 (16.7%), 14 (35.8%), 15 (5.3%), 19 (5.0%) and 23
(25.7%).
Of the penicillin-resistant SGTs 6, 14 and 23, 74.5%, 33.0%
and 26.6%, respectively, demonstrated the PTE pattern. In
contrast, 80% of SGT 9 penicillin-resistant isolates were resis-
tant to penicillin alone.
With regard to tetracycline resistance, 26 SGTs were
involved, but 59 of the 61 resistant isolates of serogroup 1were
resistant to tetracycline alone.
The three most frequently isolated SGTs of pneumococci
(6, 14, 19) accounted for 1097 (74.6%) of the 1471 erythromy-
cin-resistant strains. The TE pattern is widespread in SGTs 6
(72.8%) and19 (63.7%).
D I S C U S S I O N
The epidemiologic characteristics of the di¡erent pneumococ-
cal SGTs are extremely complex, although the leading SGTs
causing illness are the same worldwide. In Belgium, the seven
most common SGTs remained the same during the surveil-
lance of 20  years of invasive infections.
SGTs 1 and 5 are especially uncommon in the USA and
Canada, while in some European countries such as Denmark
and Germany, SGT 1 isolates are the most frequent causes of
pneumococcal infections [8,9,10]. In Spain, SGT 1was impor-
tant at the beginning of the 1980s but ranks in 1996 among the
least frequent ones [11]. In Belgium this type has maintained a
high frequencyduring this surveillance study andwas also iso-
lated with a greater frequency from blood than from other
sources but remained susceptible to penicillin. In Belgium, as
in most other European countries, SGT 3 has decreased in
recent years. SGTs 6, 14 and 19 were found more frequently in
children, regardless of source, and SGTs 3 and 9 had an
obvious predilection for adults.
Approximately 95% of our invasive strains are SGTs
included in the 23-valent pneumococcal capsular polysacchar-
ide vaccine. This vaccine has approximately 60% e¤cacy in
preventing invasive pneumococcal infection, yet, worldwide,
it is underused in the susceptible populations for whom it was
devised. In Belgium, the o¤cial recommendations were
endorsed by a consensus conference and by the scienti¢c socie-
ties; the government approved an in£uenza and pneumococ-
cal vaccine promotion campaign in the media during autumn
1997. These e¡orts resulted in a sharp increase of vaccine
uptake [12]. Perhaps the consolidation since 1997 of the yearly
Table  7 SGT distribution and resistance patterns of 1925 resistant pneumococcal isolates in Belgium (1994±98)
No. of strains resistant to
SGT P T E PT PE TE PTE Total
1 ± 59 1 ± ± 2 ± 62
3 ± 3 ± ± ± 2 1 6
4 ± 2 1 ± ± 5 ± 8
5 1 8 1 1 ± ± 1 12
6 7 11 36 3 2 195 35 289
7 ± 3 3 ± ± ± ± 6
8 1 ± 1 ± ± ± ± 2
9 72 5 15 1 2 120 15 230
10 ± 1 4 ± ± 2 ± 7
11 1 1 4 ± ± 4 ± 10
12 ± 22 ± ± ± 1 ± 23
14 114 4 274 3 13 112 64 584
15 18 4 2 ± 1 19 10 54
18 ± 7 1 ± ± ± ± 8
19 8 11 118 4 2 233 13 389
23 17 7 7 36 49 26 37 179
33 ± 1 13 1 ± 6 ± 21
Othersa 4 12 2 ± ± 12 5 35
aTypes 2, 13, 16, 17, 20, 21, 22, 24, 28, 34, 35 and 39.
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increase of the number of blood isolates received in the refer-
ence center is the result of this vaccine campaign.
The highest rates of invasive pneumococcal disease were
found in the very young and in the elderly, as described pre-
viously [13].The case fatality rate in bacteremic pneumococcal
disease increases with advancing age from about 2.3% in
young children to over 15% in the elderly. More cases have
been reported to occur in males than in females. During the
study period, 58.2% of the pneumococcal strains isolated
from blood or CSF were recovered from males. The factors
contributing to the greater susceptibility of men to invasive
pneumococcal infections are not fully understood. Alcohol-
ism and chronic obstructive pulmonary disease were noted to
be signi¢cantly more common among men than among
women in Belgium, as in most other countries. Both factors
could further contribute to the male predominance in invasive
pneumococcal infections. The increased incidence of pneu-
mococcal bacteremia and otitis media (M/F ratio: 1.36) in
boys suggests that a true sex di¡erence might exist.
Until the 1960s, S. pneumoniaewas assumed to be uniformly
susceptible to b-lactam antibiotics and macrolides, allowing
physicians to treat pneumococcal infections empirically with
penicillin and erythromycin without testing for antibiotic
susceptibility. Since 1967, resistance of S. pneumoniae to peni-
cillin and subsequently to multiple classes of antimicrobials
has been noted throughout the world. In Belgium, most iso-
lates remained susceptible until the late 1980s, with only a
small percentage of isolates displaying moderate resistance to
penicillin. Resistance to penicillin increased markedly in the
1990s, with 14% of clinical isolates now noted to have reduced
susceptibility to penicillin. However, the incidence of PRSP
has remained stable at very low levels in some areas of Europe:
Denmark, <1%; The Netherlands, <1%; and Italy, 5.5%
[9,14].
Incorporation of naked DNA that has been released from
other bacteria such as viridans streptococci is the process by
which penicillin-sensitive pneumococci are converted into
PRSP.These newly acquired genes, which code for the altered
penicillin-binding proteins in PRSP, thus contain a mixture
of native and foreign DNA (hybrid genes). Further transmis-
sion of hybrid genes frompneumococci to other pneumococci
occurs. As a result, it may be expected that penicillin resistance
will further spread to other SGTs in Belgium. It is a general
¢nding that penicillin resistance is concentrated in certain spe-
ci¢c SGTs. In Belgium, 91% of PRSP were con¢ned to only
¢ve SGTs (6, 9, 14, 19 and 23). It has also been demonstrated
that the resistant isolates of clone 23 circulating in Belgium are
serotype variants of the clone19, which originated by the hori-
zontal spread of capsular genes [15].
In Belgium, the majority of PRSP belong to the category
of intermediate resistance; only 10% of PRSPare highly resis-
tant. However, the number of pneumococci with high-level
resistance increased during 1997 and 1998. Consequently,
microbiology laboratories should routinely screen all invasive
pneumococcal isolates for penicillin resistance and perform
MIC testing for isolates found to be resistant on screening. In
the category of the highly resistant pneumococci, the level of
resistance in most isolates remains at an MIC of 2  mg/L. Only
¢ve of the 59 highly resistant pneumococci had an MIC for
penicillin of>2  mg/L. Following standard dosing, penicillin
achieves levels in the serum considerably greater than 2  mg/L
for several hours.Thus, penicillin administered intravenously
would be expected to result in clearance of pneumococcal bac-
teremia in a normal host, even in a case of full resistance [16].
Since penicillin resistance entails alterations of penicillin-
binding proteins, the activity of other b-lactam agents,
including cephalosporins and carbapenems, is also a¡ected. In
theUSA, isolates with extremely high resistance to third-gen-
eration cephalosporins but low resistance to penicillin have
been detected [17]. Fortunately, this type of resistant isolate is
very rare outside theUSA. In this study on a total of 516 pneu-
mococci with reduced susceptibility to penicillin, in only 14
(2.7%) isolates was the MIC of cefotaxime higher than that of
penicillin. Until now, only two strains with an MIC for cefo-
taxime >2  mg/L have been observed. Consequently, cef-
triaxone or cefotaxime can be recommended in Belgium for
the empirical treatment of patients with suspected bacterial
meningitis. There is no need to add vancomycin routinely to
extended-spectrum cephalosporins for empirical therapy of
meningitis [18,19].
Macrolides are among the alternative agents available for
the treatment of minor infections with PRSP. However, the
frequency of erythromycin resistance increased dramatically
from 5.5% in 1985 to 31% in 1998 and constitutes an obstacle
to empirical therapy with drugs from this family. Erythromy-
cin resistance is a particular problem in the three major SGTs
found in Belgium (14,19 and 6).
Macrolide resistance can occur either by target site modi¢-
cation or active e¥ux of the drug. In the USA, approximately
45% of macrolide resistance in S. pneumoniae is secondary to
target modi¢cation that is mediated by erm genes.The mef gene
confers macrolide resistance in the remaining 55% by an e¥ux
pump mechanism. However, in Belgium, e¥ux-based ery-
thromycin resistance is rare [20].
Ninety per cent of erythromycin-resistant pneumococci
carry the ermAM gene, resulting in high-level resistance to
erythromycin with cross-resistance to clindamycin, azithro-
mycin and clarithromycin.
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